{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:51:17Z","timestamp":1791251477685,"version":"4.1.0"},"reference-count":118,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Hypertension is a leading global cause of cardiovascular disease and mortality, with resistant hypertension (RH) posing treatment challenges. Aldosterone synthase inhibitors (ASIs) are a novel drug class that reduce blood pressure by lowering aldosterone levels. Baxdrostat is a selective ASI that inhibits the CYP11B2 enzyme, responsible for aldosterone synthesis, without affecting cortisol production. This selectivity minimizes hormonal side effects. Clinical trials have shown that baxdrostat reduces plasma aldosterone in a dose-dependent manner while preserving cortisol levels. In the Phase 2 BrigHTN trial, baxdrostat significantly lowered systolic and diastolic blood pressure in patients with RH, with the 2 mg dose showing the most consistent efficacy. However, in the HALO trial, similar blood pressure reductions were observed in the placebo group, possibly due to improved adherence to background antihypertensive therapy. Baxdrostat has demonstrated a favorable safety profile, with mostly mild adverse effects and no significant impact on kidney function. It is considered safe for use with other medications, including metformin. Ongoing trials are investigating its potential in patients with chronic kidney disease (CKD) and primary hyperaldosteronism (PA). Baxdrostat represents a promising therapeutic option for aldosterone-driven hypertension, especially in patients unresponsive to standard treatments.<\/jats:p>","DOI":"10.3390\/biom15101439","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T08:10:31Z","timestamp":1760343031000},"page":"1439","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Baxdrostat: A Next-Generation Aldosterone Synthase Inhibitor Offering New Hope in Resistant Hypertension"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6799-4746","authenticated-orcid":false,"given":"Ewelina","family":"M\u0142ynarska","sequence":"first","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Witold","family":"Czarnik","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7090-259X","authenticated-orcid":false,"given":"Natasza","family":"Dzie\u017ca","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weronika","family":"J\u0119draszak","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Majchrowicz","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Prusinowski","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3490-3480","authenticated-orcid":false,"given":"Magdalena","family":"Stabrawa","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Rysz","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Franczyk","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Burlacu, A., Kuwabara, M., Brinza, C., and Kanbay, M. (2025). Key Updates to the 2024 ESC Hypertension Guidelines and Future Perspectives. Medicina, 61.","DOI":"10.3390\/medicina61020193"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Boateng, E.B., and Ampofo, A.G. (2023). A glimpse into the future: Modelling global prevalence of hypertension. BMC Public Health, 23.","DOI":"10.1186\/s12889-023-16662-z"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(19)32008-2","article-title":"Modifiable risk factors, cardiovascular disease, and mortality in 155,722 individuals from 21 high-income, middle-income, and low-income countries (PURE): A prospective cohort study","volume":"395","author":"Yusuf","year":"2020","journal-title":"Lancet"},{"key":"ref_4","unstructured":"GBD 2017 Causes of Death Collaborators (2018). Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet, 392, 1736\u20131788. Erratum in Lancet 2019, 393, e44."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1161\/CIRCULATIONAHA.110.992362","article-title":"Hypertension: A global perspective","volume":"123","author":"Sliwa","year":"2011","journal-title":"Circulation"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40885-024-00265-w","article-title":"When and how to use ambulatory blood pressure monitoring and home blood pressure monitoring for managing hypertension","volume":"30","author":"Lee","year":"2024","journal-title":"Clin. Hypertens."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1097\/HJH.0b013e3283577b05","article-title":"The great myth of office blood pressure measurement","volume":"30","author":"Myers","year":"2012","journal-title":"J. Hypertens."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"ESC Scientific Document Group. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"d286","DOI":"10.1136\/bmj.d286","article-title":"Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: Randomised parallel design controlled trial","volume":"342","author":"Myers","year":"2011","journal-title":"BMJ"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/5584_2016_49","article-title":"Principles of Blood Pressure Measurement\u2014Current Techniques, Office vs Ambulatory Blood Pressure Measurement","volume":"956","author":"Vischer","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_11","first-page":"959","article-title":"The applicability of home blood pressure measurement in clinical practice: A review of literature","volume":"3","author":"Verberk","year":"2007","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11906-019-0916-0","article-title":"Implementing Home Blood Pressure Monitoring into Clinical Practice","volume":"21","author":"Fung","year":"2019","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/spcare-2025-005538","article-title":"Home blood pressure monitoring: Technology, digitisation and future development","volume":"15","author":"Shi","year":"2025","journal-title":"BMJ Support. Palliat. Care"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1161\/HYPERTENSIONAHA.123.21118","article-title":"Use of Different Blood Pressure Thresholds to Reduce the Number of Home Blood Pressure Monitoring Days Needed for Detecting Hypertension","volume":"80","author":"Bradley","year":"2023","journal-title":"Hypertension"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1161\/HYP.0000000000000087","article-title":"Measurement of Blood Pressure in Humans: A Scientific Statement from the American Heart Association","volume":"73","author":"Muntner","year":"2019","journal-title":"Hypertension"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.15420\/ecr.2019.11.1","article-title":"Hypertension and Stroke: Update on Treatment","volume":"14","author":"Wajngarten","year":"2019","journal-title":"Eur. Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1586\/ern.11.99","article-title":"Epidemiology and prevention of stroke: A worldwide perspective","volume":"12","author":"Kuklina","year":"2012","journal-title":"Expert Rev. Neurother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1161\/STROKEAHA.121.035850","article-title":"New Insights into Cerebrovascular Pathophysiology and Hypertension","volume":"53","author":"Webb","year":"2022","journal-title":"Stroke"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1161\/HYPERTENSIONAHA.120.14653","article-title":"Blood Pressure Management in Stroke","volume":"76","author":"Gorelick","year":"2020","journal-title":"Hypertension"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"b1665","DOI":"10.1136\/bmj.b1665","article-title":"Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies","volume":"338","author":"Law","year":"2009","journal-title":"BMJ"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2459\/JCM.0b013e3283511ee2","article-title":"Hypertension and acute myocardial infarction: An overview","volume":"13","author":"Pedrinelli","year":"2012","journal-title":"J. Cardiovasc. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"563657","DOI":"10.4061\/2011\/563657","article-title":"The impact of hypertension on patients with acute coronary syndromes","volume":"2011","author":"Picariello","year":"2011","journal-title":"Int. J. Hypertens."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Gallo, G., and Savoia, C. (2024). Hypertension and Heart Failure: From Pathophysiology to Treatment. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25126661"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jchf.2017.04.012","article-title":"The Transition From Hypertension to Heart Failure: Contemporary Update","volume":"5","author":"Messerli","year":"2017","journal-title":"JACC Heart Fail."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/eurjpc\/zwad344","article-title":"Blood pressure, hypertension, and the risk of heart failure: A systematic review and meta-analysis of cohort studies","volume":"31","author":"Baffour","year":"2024","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.jacc.2022.07.005","article-title":"Harmonization of the American College of Cardiology\/American Heart Association and European Society of Cardiology\/European Society of Hypertension Blood Pressure\/Hypertension Guidelines: Comparisons, Reflections, and Recommendations","volume":"80","author":"Whelton","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Hao, X.M., Liu, Y., Hailaiti, D., Gong, Y., Zhang, X.D., Yue, B.N., Liu, J.P., Wu, X.L., Yang, K.Z., and Wang, J. (2024). Mechanisms of inflammation modulation by different immune cells in hypertensive nephropathy. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1333170"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Costantino, V.V., Gil Lorenzo, A.F., Bocanegra, V., and Vall\u00e9s, P.G. (2021). Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan Through Hsp70. Cells, 10.","DOI":"10.3390\/cells10113146"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/HJH.0000000000003539","article-title":"A set of urinary peptides can predict early renal damage in primary hypertension","volume":"41","author":"Lin","year":"2023","journal-title":"J. Hypertens."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Arzaghi, H., Ma, Z., Roye, Y., and Musah, S. (2024). Epigenetics of Hypertensive Nephropathy. Biomedicines, 12.","DOI":"10.3390\/biomedicines12112622"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/HJH.0000000000001170","article-title":"Hypertensive nephropathy. Moving from classic to emerging pathogenetic mechanisms","volume":"35","author":"Seccia","year":"2017","journal-title":"J. Hypertens."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2958717","DOI":"10.1155\/2018\/2958717","article-title":"Combined Therapy of Hypertensive Nephropathy with Breviscapine Injection and Antihypertensive Drugs: A Systematic Review and a Meta-Analysis","volume":"2018","author":"Wu","year":"2018","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension","volume":"36","author":"Williams","year":"2018","journal-title":"J. Hypertens."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s11906-007-0057-8","article-title":"Dietary salt restriction and blood pressure in clinical trials","volume":"9","author":"Lackland","year":"2007","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Dybiec, J., Krzemi\u0144ska, J., Radzioch, E., Szlagor, M., Wronka, M., M\u0142ynarska, E., Rysz, J., and Franczyk, B. (2023). Advances in the Pathogenesis and Treatment of Resistant Hypertension. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241612911"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"36","DOI":"10.31083\/j.rcm2301036","article-title":"Overview of salt restriction in the Dietary Approaches to Stop Hypertension (DASH) and the Mediterranean diet for blood pressure reduction","volume":"23","author":"Filippou","year":"2022","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"643S","DOI":"10.1093\/ajcn\/65.2.643S","article-title":"Randomized trials of sodium reduction: An overview","volume":"65","author":"Cutler","year":"1997","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1136\/bmj.325.7365.628","article-title":"Systematic review of long term effects of advice to reduce dietary salt in adults","volume":"325","author":"Hooper","year":"2002","journal-title":"BMJ"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2185457","DOI":"10.1080\/08037051.2023.2185457","article-title":"What is resistant arterial hypertension?","volume":"32","author":"Shalaeva","year":"2023","journal-title":"Blood Press."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/ehjcvp\/pvz057","article-title":"Resistant hypertension: New insights and therapeutic perspectives","volume":"6","author":"Ruilope","year":"2020","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_43","first-page":"237","article-title":"Lifestyle Modifications to Prevent and Control Hypertension","volume":"10","author":"Samadian","year":"2016","journal-title":"Iran. J. Kidney Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"495","DOI":"10.18865\/ed.25.4.495","article-title":"Treatment Resistant Hypertension","volume":"25","author":"Egan","year":"2015","journal-title":"Ethn. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1161\/01.HYP.0000094221.86888.AE","article-title":"Influence of weight reduction on blood pressure: A meta-analysis of randomized controlled trials","volume":"42","author":"Neter","year":"2003","journal-title":"Hypertension"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamainternmed.2017.6015","article-title":"Association of Blood Pressure Lowering with Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis","volume":"178","author":"Carlberg","year":"2018","journal-title":"JAMA Intern. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","article-title":"Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5","DOI":"10.14797\/mdcvj.1175","article-title":"Pharmacotherapy for Essential Hypertension: A Brief Review","volume":"18","author":"Heidari","year":"2022","journal-title":"Methodist Debakey Cardiovasc. J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/HJH.0000000000002453","article-title":"2020 International Society of Hypertension global hypertension practice guidelines","volume":"38","author":"Unger","year":"2020","journal-title":"J. Hypertens."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1055\/s-0031-1291318","article-title":"Aldosterone and the heart: From basic research to clinical evidence","volume":"44","author":"Catena","year":"2012","journal-title":"Horm. Metab. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/169795a0","article-title":"Isolation of a highly active mineralocorticoid from beef adrenal extract","volume":"169","author":"Grundy","year":"1952","journal-title":"Natures"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.mce.2011.07.034","article-title":"Acute and chronic regulation of aldosterone production","volume":"350","author":"Hattangady","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1210\/endo-118-4-1353","article-title":"Preparation of antiserum to rat cytochrome P-450 cholesterol side chain cleavage, and its use for ultrastructural localization of the immunoreactive enzyme by protein A-gold technique","volume":"118","author":"Farkash","year":"1986","journal-title":"Endocrinology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/(SICI)1097-0029(19970315)36:6<445::AID-JEMT2>3.0.CO;2-H","article-title":"Light and electron microscopic immunohistochemistry of the localization of adrenal steroidogenic enzymes","volume":"36","author":"Ishimura","year":"1997","journal-title":"Microsc. Res. Tech."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"13187","DOI":"10.1074\/jbc.M412884200","article-title":"14-3-3 proteins modulate the expression of epithelial Na+ channels by phosphorylation-dependent interaction with Nedd4-2 ubiquitin ligase","volume":"280","author":"Ichimura","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF00232796","article-title":"Transcriptional control of sodium transport in tight epithelial by adrenal steroids","volume":"144","author":"Verrey","year":"1995","journal-title":"J. Membr. Biol."},{"key":"ref_57","unstructured":"Scott, J.H., Menouar, M.A., and Dunn, R.J. (2025). Physiology, Aldosterone. StatPearls, StatPearls Publishing."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrendo.2009.263","article-title":"Aldosterone and arterial hypertension","volume":"6","author":"Tomaschitz","year":"2010","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000345243","article-title":"Vascular actions of aldosterone","volume":"50","author":"Briet","year":"2013","journal-title":"J. Vasc. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/0267659117727826","article-title":"Left ventricular dysfunction causing ischemia in patients with patent coronary arteries","volume":"33","author":"Nguyen","year":"2018","journal-title":"Perfusion"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.118.11339","article-title":"Epithelial Sodium Channel in Aldosterone-Induced Endothelium Stiffness and Aortic Dysfunction","volume":"72","author":"Jia","year":"2018","journal-title":"Hypertension"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.ekir.2018.07.014","article-title":"Hypokalemic Nephropathy","volume":"3","author":"Yalamanchili","year":"2018","journal-title":"Kidney Int. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/2042018810380214","article-title":"Replication of cortisol circadian rhythm: New advances in hydrocortisone replacement therapy","volume":"1","author":"Chan","year":"2010","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0306-4530(99)00035-9","article-title":"The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders","volume":"25","author":"Heim","year":"2000","journal-title":"Psychoneuroendocrinology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1196\/annals.1410.012","article-title":"Limbic regulation of hypothalamo-pituitary-adrenocortical function during acute and chronic stress","volume":"1148","author":"Jankord","year":"2008","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ejphar.2007.11.071","article-title":"Central effects of stress hormones in health and disease: Understanding the protective and damaging effects of stress and stress mediators","volume":"583","author":"McEwen","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.rdc.2015.08.002","article-title":"Corticosteroids: Mechanisms of Action in Health and Disease","volume":"42","author":"Ramamoorthy","year":"2016","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"13357","DOI":"10.1073\/pnas.96.23.13357","article-title":"Down regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension","volume":"96","author":"Wallerath","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/01.HYP.27.2.184","article-title":"l-Arginine prevents corticotropin-induced increases in blood pressure in the rat","volume":"27","author":"Turner","year":"1996","journal-title":"Hypertension"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1440-1681.1997.tb01212.x","article-title":"The effects of diet on measurement of nitric oxide metabolites","volume":"24","author":"Wang","year":"1997","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0895-7061(00)01201-2","article-title":"Cortisol inhibits cholinergic vasodilation in the human forearm","volume":"13","author":"Mangos","year":"2000","journal-title":"Am. J. Hypertens."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/ndt\/12.6.1155","article-title":"Is endogenous erythropoietin a pathogenetic factor in the development of essential hypertension?","volume":"12","author":"Langenfeld","year":"1997","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.jhh.1000959","article-title":"Role of erythropoietin in cortisol induced hypertension","volume":"14","author":"Kelly","year":"2000","journal-title":"J. Hum. Hypertens."},{"key":"ref_75","first-page":"E113","article-title":"Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure","volume":"271","author":"Vaziri","year":"1996","journal-title":"Am. J. Physiol."},{"key":"ref_76","first-page":"1846","article-title":"Glucocorticoid receptor polymorphism, skin vasoconstriction, and other metabolic intermediate phenotypes in normal human subjects","volume":"83","author":"Panarelli","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/BF03349774","article-title":"Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor","volume":"18","author":"Whitworth","year":"1995","journal-title":"J. Endocrinol. Investig."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1210\/jcem-72-5-1060","article-title":"Evidence that high dose cortisol induced Na+ retention in man is not mediated by the mineralocorticoid receptor","volume":"72","author":"Clore","year":"1991","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/VHRM.S138599","article-title":"Managing resistant hypertension: Focus on mineralocorticoid-receptor antagonists","volume":"13","author":"Modolo","year":"2017","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1161\/HYPERTENSIONAHA.124.23962","article-title":"Efficacy and Safety of Aldosterone Synthase Inhibitors for Hypertension: A Meta-Analysis of Randomized Controlled Trials and Systematic Review","volume":"82","author":"Marzano","year":"2025","journal-title":"Hypertension"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"102875","DOI":"10.1016\/j.cpcardiol.2024.102875","article-title":"Efficacy and safety of aldosterone synthase inhibitors in hypertension: A systematic review and meta- analysis","volume":"49","author":"Siddiqui","year":"2024","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1210\/clinem\/dgad071","article-title":"Aldosterone Synthase Inhibitors and the Treatment of Essential Hypertension","volume":"108","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1093\/eurheartj\/ehac299","article-title":"Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"43","author":"Pandey","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.2174\/1381612825666190222144359","article-title":"Adverse Effects of Mineralocorticoid Receptor Antagonist Administration","volume":"24","author":"Kallistratos","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11102-024-01471-3","article-title":"Osilodrostat improves blood pressure and glycemic control in patients with Cushing\u2019s disease: A pooled analysis of LINC 3 and LINC 4 studies","volume":"28","author":"Fleseriu","year":"2025","journal-title":"Pituitary"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4103\/ijem.ijem_260_23","article-title":"Efficacy and Safety of Osilodrostat in Managing Cushing\u2019s Syndrome: A Systematic Review and Meta-Analysis","volume":"28","author":"Nagendra","year":"2024","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"H670","DOI":"10.1152\/ajpheart.00419.2023","article-title":"Aldosterone and aldosterone synthase inhibitors in cardiorenal disease","volume":"326","author":"Verma","year":"2024","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","article-title":"Advance-HTN Investigators. Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension","volume":"392","author":"Laffin","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Pivonello, R., Ferrigno, R., De Martino, M.C., Simeoli, C., Di Paola, N., Pivonello, C., Barba, L., Negri, M., De Angelis, C., and Colao, A. (2020). Medical Treatment of Cushing\u2019s Disease: An Overview of the Current and Recent Clinical Trials. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.00648"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1179551421994102","DOI":"10.1177\/1179551421994102","article-title":"Mifepristone as Bridge or Adjunct Therapy in the Management of Challenging Cushing Disease Cases","volume":"14","author":"Chang","year":"2021","journal-title":"Clin. Med. Insights Endocrinol. Diabetes"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"101918","DOI":"10.1016\/j.cpcardiol.2023.101918","article-title":"Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension","volume":"48","author":"Dogra","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40292-024-00634-4","article-title":"Systematic Review Article: New Drug Strategies for Treating Resistant Hypertension-the Importance of a Mechanistic, Personalized Approach","volume":"31","author":"Nardoianni","year":"2024","journal-title":"High Blood Press. Cardiovasc. Prev."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Investigators. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_95","first-page":"1808","article-title":"Revising the Roles of Aldosterone in Vascular Physiology and Pathophysiology: From Electocortin to Baxdrostat","volume":"39","author":"Feldman","year":"2023","journal-title":"Can. J. Cardiol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1097\/JIM.0000000000000220","article-title":"Aldosterone Synthase Promoter Polymorphism and Cardiovascular Phenotypes in a Large, Multiethnic Population-Based Study","volume":"63","author":"Byrd","year":"2015","journal-title":"J. Invest. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"293","DOI":"10.4103\/ijp.ijp_141_24","article-title":"Can baxdrostat revamp resistant hypertension status in India?","volume":"56","author":"Paikray","year":"2024","journal-title":"Indian J. Pharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41440-022-01070-4","article-title":"Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers","volume":"46","author":"Freeman","year":"2023","journal-title":"Hypertens. Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/bph.16247","article-title":"Taming resistant hypertension: The promise of novel pharmacologic approaches and renal denervation","volume":"181","author":"Azzam","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1161\/HYPERTENSIONAHA.116.07716","article-title":"Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2)","volume":"69","author":"Bogman","year":"2017","journal-title":"Hypertension"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJM199610173351607","article-title":"Adrenal insufficiency","volume":"335","author":"Oelkers","year":"1996","journal-title":"New Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/00000542-198412000-00003","article-title":"Etomidate inhibits adrenocortical function in surgical patients","volume":"61","author":"Wagner","year":"1984","journal-title":"Anesthesiology"},{"key":"ref_103","unstructured":"Bhatt, D. (2023). HALO Trial. AHA Congress, The American College of Cardiology. Available online: https:\/\/www.acc.org\/Latest-in-Cardiology\/Clinical-Trials\/2023\/03\/01\/23\/34\/halo."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/cpdd.1371","article-title":"Results from a Phase 1 Study Assessing the Pharmacokinetics of the Aldosterone Synthase Inhibitor Baxdrostat in Participants with Varying Degrees of Renal Function","volume":"13","author":"Freeman","year":"2024","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/ehjcvp\/pvae049","article-title":"New ways of mitigating aldosterone in cardiorenal disease","volume":"10","author":"Kunz","year":"2024","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.steroids.2014.08.014","article-title":"Brain mineralocorticoid receptors in cognition and cardiovascular homeostasis","volume":"91","year":"2014","journal-title":"Steroids"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40256-023-00572-x","article-title":"Results from a Randomized, Open-Label, Crossover Study Evaluating the Effect of the Aldosterone Synthase Inhibitor Baxdrostat on the Pharmacokinetics of Metformin in Healthy Human Subjects","volume":"23","author":"Freeman","year":"2023","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/j.1476-5381.2011.01394.x","article-title":"Importance of the multidrug and toxin extrusion MATE\/SLC47A family to pharmacokinetics, pharmacodynamics\/toxicodynamics and pharmacogenomics","volume":"164","author":"Yonezawa","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_109","unstructured":"AstraZeneca (2025, June 27). A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin on CKD Progression in Participants with CKD and High Blood Pressure. NCT06268873, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06268873?rank=1."},{"key":"ref_110","unstructured":"(2025, June 27). A Study to Investigate the Pharmacokinetics of Baxdrostat When Given Alone and in Combination with Itraconazole in Healthy Participants. Available online: https:\/\/www.astrazenecaclinicaltrials.com\/study\/D6970C00005\/."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2478\/enr-2020-0024","article-title":"The cytochrome 11B2 aldosterone synthase gene rs1799998 single nucleotide polymorphism determines elevated aldosterone, higher blood pressure, and reduced glomerular filtration, especially in diabetic female patients","volume":"54","author":"Sydorchuk","year":"2020","journal-title":"Endocr Regul."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Flack, J.M., Azizi, M., Brown, J.M., Dwyer, J.P., Jones, E.S.W., Lihn, A.S., Liu, L., Olsson, D.S., Perl, S., and Shibata, H. Baxdrostat for uncontrolled and resistant hypertension: Rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24. Hypertens Res., 2025.","DOI":"10.1038\/s41440-025-02297-7"},{"key":"ref_113","unstructured":"AstraZeneca (2025, September 24). A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension (BaxAsia). NCT06344104, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06344104."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Flack, J.M., Azizi, M., Brown, J.M., Dwyer, J.P., Fronczek, J., Jones, E.S.W., Olsson, D.S., Perl, S., Shibata, H., and Wang, J.G. (2025). Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N. Engl. J. Med., 30.","DOI":"10.1056\/NEJMoa2507109"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1097968","DOI":"10.3389\/fendo.2022.1097968","article-title":"The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension","volume":"13","author":"Forzano","year":"2022","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1056\/NEJMc2508629","article-title":"Phase 2a Study of Baxdrostat in Primary Aldosteronism","volume":"393","author":"Turcu","year":"2025","journal-title":"N Engl. J. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1159\/000542621","article-title":"Aldosterone Synthase Inhibitors for Cardiorenal Protection: Ready for Prime Time?","volume":"49","author":"Mazzieri","year":"2024","journal-title":"Kidney Blood Press Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e70080","DOI":"10.1111\/bcpt.70080","article-title":"Blood Pressure-Lowering Effects of Aldosterone Synthase Inhibitors-A Systematic Review","volume":"137","author":"Rasmussen","year":"2025","journal-title":"Basic Clin. Pharmacol. Toxicol."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/10\/1439\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T04:25:14Z","timestamp":1760502314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/10\/1439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":118,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["biom15101439"],"URL":"https:\/\/doi.org\/10.3390\/biom15101439","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,11]]}}}